Osteoarthritis

You have full text access to this OnlineOpen article

The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the glucosamine/chondroitin arthritis intervention trial†

  1. Allen D. Sawitzke1,*,
  2. Helen Shi2,
  3. Martha F. Finco1,
  4. Dorothy D. Dunlop3,
  5. Clifton O. Bingham III4,‡,
  6. Crystal L. Harris5,
  7. Nora G. Singer6,§,
  8. John D. Bradley7,
  9. David Silver8,
  10. Christopher G. Jackson1,
  11. Nancy E. Lane9,
  12. Chester V. Oddis10,
  13. Fred Wolfe11,
  14. Jeffrey Lisse12,
  15. Daniel E. Furst13,
  16. Domenic J. Reda2,
  17. Roland W. Moskowitz6,¶,
  18. H. James Williams1,
  19. Daniel O. Clegg1,‖

Article first published online: 29 SEP 2008

DOI: 10.1002/art.23973

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 58, Issue 10, pages 3183–3191, October 2008

Additional Information

How to Cite

Sawitzke, A. D., Shi, H., Finco, M. F., Dunlop, D. D., Bingham, C. O., Harris, C. L., Singer, N. G., Bradley, J. D., Silver, D., Jackson, C. G., Lane, N. E., Oddis, C. V., Wolfe, F., Lisse, J., Furst, D. E., Reda, D. J., Moskowitz, R. W., Williams, H. J. and Clegg, D. O. (2008), The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the glucosamine/chondroitin arthritis intervention trial. Arthritis & Rheumatism, 58: 3183–3191. doi: 10.1002/art.23973

Author Information

  1. 1

    University of Utah School of Medicine, Salt Lake City

  2. 2

    Hines VA Cooperative Studies Program Coordinating Center, Hines, Illinois

  3. 3

    Northwestern University Feinberg School of Medicine, Chicago, Illinois

  4. 4

    Johns Hopkins University, Baltimore, Maryland

  5. 5

    Albuquerque VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico

  6. 6

    Case Western Reserve University, Cleveland, Ohio

  7. 7

    Indiana University, Indianapolis

  8. 8

    Cedars Sinai Medical Center, Los Angeles, California

  9. 9

    University of California, Davis, Sacramento

  10. 10

    University of Pittsburgh, Pittsburgh, Pennsylvania

  11. 11

    Arthritis Research Center, Wichita, Kansas

  12. 12

    University of Arizona, Tucson

  13. 13

    University of California, Los Angeles

  1. ‡

    Dr. Bingham has received consulting fees from Merck and McNeil (less than $10,000 each).

  2. §

    Dr. Singer has received consulting fees, speaking fees, and/or honoraria from Bristol-Myers Squibb (less than $10,000) and from Abbott Immunology (more than $10,000); she has received grants and/or contracts through the University of California, Davis from the Alliance for Lupus Research, Pfizer, Merck, Endo, Zymogenetics, Serono, Genentech, Amgen, and Roche.

  3. Dr. Moskowitz has received speaking fees and honoraria from Bioiberica (more than $10,000).

  4. ‖

    Dr. Clegg has received consulting fees, speaking fees, and/or honoraria from Bioiberica (less than $10,000), and has received grants and contracts through the University of Utah from Bioiberica.

*University of Utah School of Medicine, 30E 1900 S SOM 4B200, Salt Lake City, UT 84132

  1. †

    ClinicalTrials.gov identifier: NCT00032890.

Publication History

  1. Issue published online: 29 SEP 2008
  2. Article first published online: 29 SEP 2008
  3. Manuscript Accepted: 14 JUL 2008
  4. Manuscript Received: 11 MAR 2008

Funded by

  • NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases and National Center for Complementary and Alternative Medicine). Grant Number: N01-AR-2236

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (119K)

REFERENCES

  • 1
    Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58: 15–25.
    Direct Link:
  • 2
    Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58: 26–35.
    Direct Link:
  • 3
    Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000; 133: 635–46.
  • 4
    Brandt KD, Radin EL, Dieppe PA, van de Putte L. Yet more evidence that osteoarthritis is not a cartilage disease. Ann Rheum Dis 2006; 65: 1261–4.
  • 5
    Wollheim FA. Early stages of osteoarthritis: the search for sensitive predictors. Ann Rheum Dis 2003; 62: 1031–2.
  • 6
    Brandt KD, Mazzuca SA, Conrozier T, Dacre JE, Peterfy CG, Provvedini D, et al. Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? J Rheumatol 2002; 29: 1308–20.
  • 7
    Mazzuca SA, Brandt KD, Buckwalter KA, Lane KA, Katz BP. Field test of the reproducibility of the semiflexed metatarsophalangeal view in repeated radiographic examinations of subjects with osteoarthritis of the knee. Arthritis Rheum 2002; 46: 109–13.
    Direct Link:
  • 8
    Ravaud P, Giraudeau B, Auleley GR, Drape JL, Rousselin B, Paolozzi L, et al. Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis. Ann Rheum Dis 1998; 57: 624–9.
  • 9
    Lequesne M, Brandt K, Bellamy N, Moskowitz R, Menkes CJ, Pelletier JP, et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol Suppl 1994; 41: 65–71.
  • 10
    Buckland-Wright JC, Wolfe F, Ward RJ, Flowers N, Hayne C. Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and schuss views. J Rheumatol 1999; 26: 2664–74.
  • 11
    Wolfe F, Lane NE, Buckland-Wright C. Radiographic methods in knee osteoarthritis: a further comparison of semiflexed (MTP), schuss-tunnel, and weight-bearing anteroposterior views for joint space narrowing and osteophytes. J Rheumatol 2002; 29: 2597–601.
  • 12
    Buckland-Wright JC, Ward RJ, Peterfy C, Mojcik CF, Leff RL. Reproducibility of the semiflexed (metatarsophalangeal) radiographic knee position and automated measurements of medial tibiofemoral joint space width in a multicenter clinical trial of knee osteoarthritis. J Rheumatol 2004; 31: 1588–97.
  • 13
    Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795–808.
  • 14
    McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 284: 1469–75.
  • 15
    Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
  • 16
    Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005; 52: 779–86.
    Direct Link:
  • 17
    Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–23.
  • 18
    Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251–6.
  • 19
    Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16: 494–502.
  • 20
    Rosset A, Spadola L, Ratib O. OsiriX: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging 2004; 17: 205–16.
  • 21
    Buckland-Wright JC, Messent EA, Bingham CO III, Ward RJ, Tonkin C. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 2007; 46: 257–64.
  • 22
    Mazzuca SA, Brandt KD, Katz BP, Lane KA, Buckwalter KA. Comparison of quantitative and semiquantitative indicators of joint space narrowing in subjects with knee osteoarthritis. Ann Rheum Dis 2006; 65: 64–8.
  • 23
    Bingham CO III, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006; 54: 3494–507.
    Direct Link:
  • 24
    Hochberg Y, Tamhane AC. Multiple comparison procedures. New York: John Wiley & Sons; 1987.
  • 25
    Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514–22.
  • 26
    Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(3 Suppl ): S178–89.
  • 27
    Conrozier T. Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6). Presse Med 1998; 27: 1862–5. In French.
  • 28
    Malaise MG, Marcolongo R, Uebelhart D, Vignon E. Efficacy and tolerability of 800 mg chondroitin 4&6 sulfate in the treatment of knee osteoarthritis: a randomised, double-blind, muticentre study versus placebo. Litera Rheumatologica 1999; 24: 21–30.
  • 29
    Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998; 6 Suppl A: 39–46.
  • 30
    Kahan A. STOPP (Study on Osteoarthritis Progression Prevention): a new two-year trial with chondroitin 4&6 sulfate (CS) [abstract]. European League Against Rheumatism: Abstracts from the 2006 Annual Scientific Meeting. URL: www.ibsa-ch.com/eular-2006.amsterdam-vignon-2.pdf.
  • 31
    Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146: 580–90.
  • 32
    Jackson CG, Plaas AH, Barkhill JG, Harris CL, Clegg DO. The pharmacokinetics of oral glucosamine and chondroitin sulfate in humans [abstract]. Arthritis Rheum 2005; 52: 4062–3.
  • 33
    Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker F. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; 2: 519–22.
  • 34
    Williams HJ, Ward JR, Egger MJ, Neuner R, Brooks RH, Clegg DO, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993; 36: 1196–206.
    Direct Link:
  • 35
    Tindall EA, Sharp JT, Burr A, Katz TK, Wallemark CB, Verburg K, et al. A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib. Clin Ther 2002; 24: 2051–63.
  • 36
    Cline GA, Meyer JM, Stevens R, Buckland-Wright C, Peterfy C, Beary JF. Comparison of fixed flexion, fluoroscopic semi-flexed and MTP radiographic methods for obtaining the minimum medial joint space width of the knee in longitudinal osteoarthritis trials. Osteoarthritis Cartilage 2006; 14 Suppl A: A32–6.
  • 37
    Buckland-Wright C. Review of the anatomical and radiological differences between fluoroscopic and non-fluoroscopic positioning of osteoarthritic knees. Osteoarthritis Cartilage 2006; 14 Suppl A: A19–31.
  • 38
    Nevitt MC, Sharma L. OMERACT workshop radiography session 1. Osteoarthritis Cartilage 2006; 14 Suppl A: A4–9.
  • 39
    Mazzuca SA, Brandt KD, Buckwalter KA. Detection of radiographic joint space narrowing in subjects with knee osteoarthritis: longitudinal comparison of the metatarsophalangeal and semiflexed anteroposterior views. Arthritis Rheum 2003; 48: 385–90.
    Direct Link:
  • 40
    Brandt KD. Translating osteoarthritis into numbers: the importance of alignment in knee radiography for clinical trials of structure-modifying drugs [editorial]. Arthritis Rheum 2005; 52: 1343–5.
    Direct Link:
  • 41
    Amin S, LaValley MP, Guermazi A, Grigoryan M, Hunter DJ, Clancy M, et al. The relationship between cartilage loss on magnetic resonance imaging and radiographic progression in men and women with knee osteoarthritis. Arthritis Rheum 2005; 52: 3152–9.
    Direct Link:
  • 42
    Dupuis DE, Beynnon BD, Richard MJ, Novotny JE, Skelly JM, Cooper SM. Precision and accuracy of joint space width measurements of the medial compartment of the knee using standardized MTP semi-flexed radiographs. Osteoarthritis Cartilage 2003; 11: 716–24.
  • 43
    Mazzuca SA, Brandt KD, Buckwalter KA, Lequesne M. Pitfalls in the accurate measurement of joint space narrowing in semiflexed, anteroposterior radiographic imaging of the knee. Arthritis Rheum 2004; 50: 2508–15.
    Direct Link:
  • 44
    Conrozier T, Mathieu P, Piperno M, Favret H, Colson F, Vignon M, et al. Selection of knee radiographs for trials of structure-modifying drugs in patients with knee osteoarthritis: a prospective, longitudinal study of Lyon schuss knee radiographs with the definition of adequate alignment of the medial tibial plateau. Arthritis Rheum 2005; 52: 1411–7.
    Direct Link:
  • 45
    Le Graverand MP, Mazzuca S, Lassere M, Guermazi A, Pickering E, Brandt K, et al. Assessment of the radioanatomic positioning of the osteoarthritic knee in serial radiographs: comparison of three acquisition techniques. Osteoarthritis Cartilage 2006; 14 Suppl A: A37–43.
  • 46
    Hunter DJ, Zhang YQ, Niu JB, Tu X, Amin S, Clancy M, et al. The association of meniscal pathologic changes with cartilage loss in symptomatic knee osteoarthritis. Arthritis Rheum 2006; 54: 795–801.
    Direct Link:
  • 47
    Vignon E, Piperno M, Le Graverand MP, Mazzuca SA, Brandt KD, Mathieu P, et al. Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and Lyon schuss views. Arthritis Rheum 2003; 48: 378–84.
    Direct Link:
View Full Article (HTML) Get PDF (119K)